Recently added articles from Pharmaceutical Executive:
INDUSTRY INSIGHTS
Jan 01, 2009; ... Go to www.PharmExec.com to read these exclusive stories and other featured content. CLINICAL TRIALS Optimize Docs' Offices for Trials More than 60 percent of US trials are conducted at physicians' offices, but pharma has failed to address the challenges these test sites ...
Getting Across
Jan 01, 2009; ... The cover of this month's Pharm Exec may look as if it's about disaster, but that's not the way we meant it. It's not about falling off a cliff; it's about crossing a bridge that extends from yesterday, and an old, failing way of doing things, to tomorrow, and a revitalized pursuit of new (still ...
Advocates Jump on Stimulus Bandwagon
Jan 01, 2009; ... FINANCE Everyone wants a piece of the pie Congress and the new administration are poised to spend billions bailing out failing corporations and spurring economic recovery. Not surprisingly, everybody wants a piece of the pie. State governors are seeking $30 billion to bolster ...
Malaria Treatment on the Horizon
Jan 01, 2009; ... VACCINES GSK vaccine proves positive in clinical trials A vaccine to prevent malaria could be close. Two new studies published in the New England Journal of Medicine showed that a product being developed by GlaxoSmithKline gave babies and young children substantial protection ...
Patient Adherence Proves Value to Payors
Jan 01, 2009; ... UPCOMING WEBCAST Friday, January 30th, 2009 12 noon EST Pharma is facing a new reality: As never before, key customers-from prescription drug plans to government to large medical practices - are demanding data on patient outcomes. As pharma companies scramble to meet these new ...
Osiris: A League of Its Own?
Jan 01, 2009; ... Stem cell therapy, once considered lofty science made accessible only through the debate on their use, is steadily marching to market. Osiris Therapeutics is furthest along with Prochymal, widely expected to be the first ever FDA-approved stem cell drug, which will be submitted to the Agency for ...
DTC Advertising Under Fire
Jan 01, 2009; ... MARKETING Waxman to seek curbs on TV ads for newly approved drugs DTC advertising is back in the spotlight amid renewed efforts to impose some kind of ban on broadcast ad- vertising. Rep. Henry Waxman (D-CA) voiced support for legislation that gives FDA authority to halt DTC ...
uneven landscape
Jan 01, 2009; ... The Hay Group's 9th Annual Sales Force Survey points to sprouting opportunities amid the harsh soil of pharma's "rightsizing" quality over quantity, a more tenured sales force, and yes, even some exciting double-digit growth were bright spots for pharma in 2008, a year which saw company ...
UP IN THE AIR
Jan 01, 2009; ... With Obama in charge and the economy in the toilet, 2009 will bring enormous challenges and bigger changes. So why do our experts say, "It's all good"? If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it ...
Fair Market Value
Jan 01, 2009; ... With no formal fair market value guidelines imposed by the government, how "fair" is it for pharma to play by the rules? Eli Lilly was one of the first major drug makers to voluntarily report payments to physicians. Today, other Big Pharmas are following sui, and it's no surprise. The ...
FDA Turnaround Time
Jan 01, 2009; ... Will more resources and new leadership fix FDA, or is a major overhaul in order? First, there was the international heparin crisis. Then more contaminated food, a crackdown on cough-and-cold medicines for children, melamine in baby formula, and multiple drug safety issues. The Science ...
OVERLOOKED OPPORTUNITY
Jan 01, 2009; ... Change the patients, not the drug, by way of diagnostics If you look at pharma's pipeline, you'll see that personalized medicine is powering drug development. Every major pharma company has a biomarker development program to bring new targeted therapies to market. But there's also an ...
Pharma Confidential
Jan 01, 2009; ... How hopeful are execs about the future of their own companies and the industry in general? In these tough times, how does pharma see its future? How confident are top executives in the future of the industry and their own company? Does size make a difference? These were among the ...
The Communications Convergence
Jan 01, 2009; ... Because they have often been subject to greater scrutiny, biotech companies have set a new standard for communications This fall, Dendreon Corp. stood at a crossroads. The company was announcing key interim data on its lead product, Provenge, after more than a year's worth of speculation ...
Getting Graphic
Jan 01, 2009; ... The graphic novel emerges as a versatile, effective medical education and marketing tool When the National Kidney Foundation was looking for a more effective way to educate patients about the challenges of dialysis, they decided to take a unique approach: They created a graphic novel to ...
PHARMA VS. PHARMA
Jan 01, 2009; ... Like products, industries have life cycles. And pharma's current stage is about competition, competition, competition I ncreasing numbers of low-cost and substitute products. Intense cost pressures. Falling prices and profits. Dramatically higher R&D costs. Fewer new, innovative ...
Deal With It
Jan 01, 2009; ... When life gives them lemons, leaders roll up their sleeves and find a lemon distributor Months into the global financial crisis, the world continues to dedicate vast amounts of energy to worrying. Government officials issue lengthy statements to calm the markets; accountants spin their ...
Reasons to Believe
Dec 01, 2008; ... Maybe what you're feeling isn't impending doom. Maybe it's just growing pains The other day I was invited to give a talk at an industry event. I spoke about some of the challenges I see coming for the industry, then sat down and listened while Doug Long from IMS Health gave a ...
Reshaping R&D at Merck
Dec 01, 2008; ... Go online now to check out an exclusive Pharm Exec interview with Dr. Kathleen Metters, senior vice president, worldwide basic research, for Merck Research Laboratories. If you just read the news of Merck's last earnings report, it sounded like the company was hacking away at R&D ...
Audio Special
Dec 01, 2008; ... Beyond the Company of the Year: Dr. Bill Trombetta explains the art of the Industry Audit In a new podcast version of one of Pharm Exec's most popular features of the year, Bill Trombetta, ...